Why Factor XIa Is a Compelling Target for Stroke Prevention

Factor XIa occupies a uniquely attractive position in the coagulation cascade because it contributes disproportionately to pathological thrombus formation relative to its role in normal hemostasis. This mechanistic asymmetry — amplifying thrombin generation via the intrinsic pathway while being largely dispensable for primary hemostasis — is the central rationale for targeting FXIa in stroke prevention, and it is explicitly invoked across patent families from PatSnap’s drug discovery intelligence dataset covering Novartis, Janssen, and Bristol-Myers Squibb.

The human genetic case is compelling. Severe FXI deficiency — hemophilia C — is associated with reduced ischemic stroke and deep vein thrombosis risk. Conversely, elevated FXI levels correlate with increased venous thromboembolism and ischemic stroke risk. This bidirectional genetic evidence, cited across all major assignee patent families in the dataset, validates the target before a single drug candidate enters the clinic.

FXIa operates downstream of FXII and plasma kallikrein, and upstream of FIX, FX, and thrombin. Inhibiting it dampens thrombin amplification without substantially impairing the extrinsic (tissue factor) pathway that drives primary hemostasis. According to WIPO-registered patent filings from BMS and Janssen, this selectivity is the mechanistic basis for the predicted low-bleeding-risk profile that distinguishes FXIa inhibitors from conventional anticoagulants such as warfarin or factor Xa inhibitors.

Four distinct therapeutic modalities are being pursued against FXI/FXIa in the dataset: direct small-molecule active-site inhibitors, monoclonal antibodies targeting the catalytic domain, antisense oligonucleotides (ASOs) reducing FXI synthesis, and single-domain antibodies targeting FXI’s apple domains. The breadth of modality investment reflects the confidence that has accumulated around this target since the Ionis FXI-ASO Phase II results were published in the New England Journal of Medicine in 2015.

Milvexian and Asundexian: Phase II Evidence and Patent Claims

Milvexian is the furthest advanced orally bioavailable FXIa inhibitor in the dataset, with Phase II clinical data in both VTE prevention and secondary stroke prevention. It is a direct-acting, reversible, macrocyclic compound — its full chemical name identifies a pyrazole-pyridine-pyrimidine scaffold — that binds and inhibits activated FXIa with high affinity and selectivity versus related serine proteases.

The pivotal Phase II reference embedded across multiple BMS and Janssen patent specifications is the AXIOMATIC-SSP trial, published in The Lancet Neurology in 2023 (vol. 23, pp. 46–59), described as a “phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial” for secondary stroke prevention. Prior to that, the AXIOMATIC-TKR trial — published in the New England Journal of Medicine in 2021 (Weitz et al., vol. 385, no. 23, pp. 2161–72) — established the first human evidence for milvexian in VTE prevention using a total knee replacement model.

“Milvexian’s macrocyclic pyrazole-pyridine-pyrimidine structure provides high FXIa selectivity versus related serine proteases — a key differentiation claimed across BMS and Janssen filings spanning WO, TW, BR, AU, NZ, CN, and KR jurisdictions.”

Asundexian’s story in the dataset is defined by the PACIFIC-Stroke Phase II trial. The trial evaluated three doses — 10 mg, 20 mg, and 50 mg once daily for 26–52 weeks — added to standard antiplatelet therapy in patients after acute non-cardioembolic ischemic stroke. The result, as documented in the milvexian WO filing, was neutral: asundexian “did not reduce the composite of covert brain infarction or ischemic stroke and did not increase the composite of major or clinically relevant non-major bleeding.” The preserved safety signal is notable, but the lack of efficacy in a non-cardioembolic population raises important questions about patient selection that are discussed in the strategic implications section.

BMS has also filed patents on a tetrahydroisoquinoline scaffold containing substituted azoles as selective FXIa inhibitors or dual FXIa/plasma kallikrein inhibitors — providing structural IP underpinning for the milvexian-class chemistry and signalling interest in next-generation compounds that could simultaneously target both FXIa and contact activation pathway mediators.

Antibody Programs: Novartis, Anthos, and the ESRD Niche

The anti-FXI/FXIa monoclonal antibody space is dominated in this dataset by Novartis AG, whose patent activity spans WO, US, EP, JP, AU, CA, CN, and IL jurisdictions — the broadest multi-jurisdictional footprint in the entire retrieved set. Novartis’s antibodies target the catalytic domain of FXI/FXIa, with NOV1401 achieving aPTT prolongation of 2–3-fold and reduction of plasma FXI activity to 5–12% of baseline in preclinical primate studies.

The strategic focus of the Novartis program is a population that oral small molecules cannot easily address: patients with end-stage renal disease (ESRD) and atrial fibrillation. Conventional direct oral anticoagulants (DOACs) rely on renal clearance and carry excessive bleeding risk in dialysis patients, who are therefore excluded from DOAC clinical studies. Novartis’s filings spanning 2018–2025 explicitly claim stroke prevention and thromboembolic disorder management in dialysis patients, extracorporeal membrane oxygenation settings, and non-valvular AF with chronic kidney disease — a defensible niche with limited competitive overlap from oral small molecules.

Anthos Therapeutics represents an important emerging layer in the antibody IP landscape. Its 2025 JP patent filing covers dosing regimens for reversing anti-FXI/FXIa antibody anticoagulant effects using recombinant activated Factor VIIa (rFVIIa) at doses around 150 mg of the antibody. The existence of a reversal strategy patent is a positive translational signal: it indicates that the antibody class is approaching or in clinical stages where periprocedural management and bleeding reversal protocols are required. It also represents a potential IP moat for clinical adoption of the antibody class.

The dataset also includes two additional antibody programs targeting mechanistically distinct epitopes. Adimab, LLC filed patents for anticoagulant FXI antibodies that bind the Apple 2 domain of FXI and inhibit FXI activation by Factor XIIa — a mechanistically upstream point of inhibition relative to catalytic domain-targeted agents. Suzhou Kanningjierui Biotechnology Co., Ltd. filed patents covering single-domain antibodies targeting FXI dimerization-critical residues in the Apple 4 domain, distinguished from conventional monoclonal antibodies by their smaller molecular size and potential for alternative formulation. Both programs are at the preclinical stage per the retrieved records, but their CN and JP patent filings signal active domestic Chinese development of FXI biologics.

The foundational clinical proof-of-concept for FXI suppression comes from the Ionis Pharmaceuticals FXI-ASO program, where the Phase II study published by Buller et al. in the New England Journal of Medicine in 2015 (vol. 372, pp. 232–240) demonstrated dose-dependent VTE reduction versus enoxaparin in total knee replacement patients with fewer bleeding events. That result, cited across multiple assignee patent families, established the therapeutic validity of the FXI target before any small molecule or antibody had reached the clinic. The ASO approach requires parenteral administration — cited as a limitation relative to oral small molecules — but its clinical validation remains foundational to the entire field, as recognised by standards bodies such as EMA in their evolving guidance on oligonucleotide therapeutics.

Patent Landscape: Assignees, Jurisdictions, and Indication Expansion

The FXIa inhibitor patent landscape is dominated by a small number of large commercial organisations, with no significant academic-only patent presence on the core programs. Filing activity is concentrated in five assignees: Bristol-Myers Squibb, Janssen Research & Development, Novartis AG, Anthos Therapeutics, and Ionis Pharmaceuticals — each occupying a distinct segment of the IP space.

Bristol-Myers Squibb is the most active assignee for milvexian-specific filings, with patents covering VTE prevention, ischemic stroke, and ACS across WO, TW, BR, AU, and NZ jurisdictions. Janssen Research & Development co-develops milvexian and holds CN and KR filings for ischemic stroke and ACS contexts, reflecting Asia-Pacific commercial positioning. The BMS-Janssen collaboration thus spans complementary geographic territories with minimal overlap — a coordinated global IP strategy.

Indication expansion is a defining feature of the most recent filing cohort (2024–2025). Multiple BMS and Janssen filings extend milvexian to adverse cerebrovascular and cardiovascular event prevention in acute coronary syndrome (ACS) patients — a significant expansion beyond stroke into the broader cardiovascular prevention space. A 2025 Janssen CN filing covers milvexian for “thrombotic conditions in patients with cardiovascular or cerebrovascular disease” broadly, suggesting a maintenance-of-anticoagulation positioning across multiple vascular territories. This mirrors the trajectory seen with earlier anticoagulant classes, where initial approval in one indication (VTE) was followed by expansion into AF, ACS, and secondary prevention — a pattern documented by FDA approval histories for factor Xa inhibitors.

Several combination strategies are also emerging in the patent record. The PACIFIC-Stroke design (asundexian added to standard antiplatelet care) and references to dual antiplatelet therapy limitations in non-cardioembolic stroke suggest FXIa inhibitors are being positioned as additive to, rather than replacing, antiplatelet regimens. Novartis antibody claims include a specific aspect covering anti-FXI antibody combined with one or more statin therapies for thromboembolic disease management — an unusual IP claim that may reflect mechanistic or clinical co-administration rationale. Anthos Therapeutics’ rFVIIa reversal combination is a third combination approach, addressing the clinical safety management toolkit rather than efficacy enhancement.

Strategic Implications for Drug Developers and IP Teams

Milvexian’s trajectory — Phase II stroke data, Phase II VTE data, and active patent filings across six jurisdictions for two indications — makes it the reference asset for oral FXIa inhibitor development. Drug developers entering this space should treat the ACS indication expansion as a potential high-value second indication: the 2024–2025 BMS and Janssen filing cohort is consistent with a pre-Phase III IP consolidation strategy, filing broad claims ahead of pivotal trial data.

The PACIFIC-Stroke neutral result for asundexian represents a class-level challenge that warrants careful reading. The trial enrolled non-cardioembolic ischemic stroke patients — a population in which FXIa-driven thrombus formation may be less dominant than in cardioembolic stroke, where atrial fibrillation-associated thrombi are more dependent on the intrinsic pathway. IP strategists should monitor dose and subgroup claims in subsequent filings as potential differentiation vectors: if high-FXI-expressing patient subgroups show differential benefit, biomarker-stratified claims could become a key IP battleground, consistent with precision medicine trends tracked by NIH‘s precision medicine initiative.

Novartis’s ESRD/AF antibody program occupies a defensible niche that oral small molecules cannot easily contest. The unmet need in dialysis patients is explicitly claimed across Novartis filings spanning 2018–2025 in eight jurisdictions, and the absence of renal clearance concerns makes antibody-based FXIa inhibition structurally better suited to this population. Biosimilar or biobetter entrants from Chinese domestic programs (Suzhou Kanningjierui) are a medium-term competitive risk in the CN market, but the breadth of Novartis’s existing CN filings provides a meaningful IP barrier.

The Anthos Therapeutics reversal agent patent is the most forward-looking signal in the dataset. Reversal strategies are required by regulators and payers before broad clinical adoption of any anticoagulant class — the precedent set by idarucizumab (dabigatran reversal) and andexanet alfa (factor Xa inhibitor reversal) is instructive. The 2025 JP filing for rFVIIa-based reversal of anti-FXI antibody anticoagulation signals that the antibody class is approaching the clinical stage at which reversal protocols become a prerequisite for approval and adoption. Teams developing FXIa antibodies should treat reversal agent IP as a strategic priority, not an afterthought.

“The 2025 Anthos Therapeutics reversal agent patent — covering rFVIIa-based reversal of anti-FXI/FXIa antibody anticoagulation — signals that the antibody class is approaching clinical stages where procedural management protocols are required: a positive translational signal and a potential IP moat for clinical adoption.”

For IP teams conducting freedom-to-operate analyses, the dataset reveals a clear division of labour: BMS/Janssen own the oral small-molecule space across Western and APAC markets; Novartis owns the antibody space across all major jurisdictions; and the emerging modalities (single-domain antibodies, ASOs for stroke) remain relatively open. The tetrahydroisoquinoline/azole scaffold patents filed by BMS in 2019 (ES jurisdiction) cover dual FXIa/plasma kallikrein inhibition — a potential next-generation direction that any team developing contact-pathway-targeting compounds should assess carefully. PatSnap’s patent analytics platform provides the claim-level analysis needed to map these boundaries accurately.

No retrieved records contain regulatory submission data, approval status, or Phase III completed trial results for any FXIa inhibitor in stroke prevention. All clinical signals in the dataset are Phase II. The field is moving rapidly, and the patent filing velocity in 2024–2025 — particularly the ACS indication expansion — suggests Phase III programmes are either underway or imminent for milvexian.